These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 34053594)

  • 1. Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.
    Zheng C; Tosti A
    Dermatol Clin; 2021 Jul; 39(3):407-415. PubMed ID: 34053594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
    Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
    J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
    Lensing M; Jabbari A
    Front Immunol; 2022; 13():955035. PubMed ID: 36110853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
    Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
    J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase inhibitors for alopecia areata.
    King BA; Craiglow BG
    J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells.
    Kim JE; Lee YJ; Park HR; Lee DG; Jeong KH; Kang H
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib for the Treatment of Alopecia Areata.
    Freitas E; Guttman-Yassky E; Torres T
    Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
    Yu L; Yu H; Zhang S; Hao Y; Zhang S
    Front Immunol; 2022; 13():904156. PubMed ID: 35795663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
    Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib: A Review in Severe Alopecia Areata.
    Fung S; Shirley M
    Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
    Stefanis AJ
    Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
    Trüeb RM; Dias MFRG
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):68-87. PubMed ID: 28717940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
    Ramot Y; Zlotogorski A
    Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
    Liu LY; King BA
    J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
    Passeron T; King B; Seneschal J; Steinhoff M; Jabbari A; Ohyama M; Tobin DJ; Randhawa S; Winkler A; Telliez JB; Martin D; Lejeune A
    Front Immunol; 2023; 14():1243556. PubMed ID: 38022501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for alopecia areata: JAK inhibitors.
    Iorizzo M; Tosti A
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):77-81. PubMed ID: 29466675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth.
    Schwartzberg L; Spizuoco A
    Cutis; 2023 Nov; 112(5):E5-E9. PubMed ID: 38091428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
    Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
    JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.